NCT06629584 2026-02-17
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
3 trialsNCT04492033 2025-01-27
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
Phase 1/2 Terminated
NCT03292783 2021-07-07
This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
ABL Bio, Inc.
Phase 1 Completed